Key Points
- COO Jose Manuel Otero sold 3,016 shares on Feb. 18 at an average price of $6.40 for $19,302.40, cutting his stake by 2.35% to 125,460 shares (≈$802,944).
- Analyst sentiment is broadly positive — MarketBeat shows an average rating of "Moderate Buy" with a consensus price target of $19.00 (1 Strong Buy, 8 Buy, 1 Sell).
- Trading and fundamentals — LXEO traded near $6.29 with a market cap of ~$459.11M, a 52-week range of $1.45–$10.99, 50-/200-day SMAs of $8.30/$7.63, and about 60.7% institutional ownership.
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) COO Jose Manuel Otero sold 3,016 shares of the company's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $6.40, for a total value of $19,302.40. Following the sale, the chief operating officer owned 125,460 shares of the company's stock, valued at approximately $802,944. The trade was a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Lexeo Therapeutics Stock Performance
Shares of NASDAQ LXEO traded up $0.02 during mid-day trading on Friday, reaching $6.29. The company had a trading volume of 659,585 shares, compared to its average volume of 740,432. The firm has a market cap of $459.11 million, a price-to-earnings ratio of -2.33 and a beta of 1.78. The business's 50-day simple moving average is $8.30 and its 200 day simple moving average is $7.63. Lexeo Therapeutics, Inc. has a one year low of $1.45 and a one year high of $10.99.
Wall Street Analysts Forecast Growth
LXEO has been the topic of several analyst reports. Oppenheimer reiterated an "outperform" rating and set a $20.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. Wall Street Zen upgraded Lexeo Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 8th. Cantor Fitzgerald started coverage on Lexeo Therapeutics in a report on Monday, December 1st. They issued an "overweight" rating and a $19.00 target price on the stock. HC Wainwright decreased their price target on Lexeo Therapeutics from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, January 13th. Finally, Raymond James Financial began coverage on Lexeo Therapeutics in a research report on Wednesday, December 17th. They set a "strong-buy" rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Lexeo Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $19.00.
Get Our Latest Stock Report on LXEO
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of LXEO. Allworth Financial LP boosted its holdings in shares of Lexeo Therapeutics by 1,002.9% during the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company's stock valued at $34,000 after acquiring an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company's stock valued at $35,000 after purchasing an additional 1,459 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Lexeo Therapeutics by 123.7% during the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company's stock valued at $39,000 after purchasing an additional 2,148 shares in the last quarter. CWM LLC grew its holdings in shares of Lexeo Therapeutics by 150.3% during the second quarter. CWM LLC now owns 10,351 shares of the company's stock worth $42,000 after purchasing an additional 6,216 shares during the last quarter. Finally, Ethic Inc. acquired a new position in shares of Lexeo Therapeutics in the second quarter valued at approximately $44,000. 60.67% of the stock is currently owned by institutional investors.
About Lexeo Therapeutics
(
Get Free Report)
Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.
The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
